Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.
- To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.
- In addition, Ovid is eligible to receive non-dilutive capital from Takeda, if and when soticlestat is successfully approved and marketed.
- Business development strategy: Ovid intends to conduct disciplined business development activities with a focus on clinical stage assets and enabling technologies to complement its portfolio of anti-seizure medicines.
- The annual decrease was a result of the above mentioned cost cutting and personnel reduction efforts undertaken in 2022.